DOCSLIB.ORG

National Preferred Formulary January 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

National Preferred Formulary January 2021 How to Use the Formulary The Formulary is a list of medications available to members under their pharmacy benefit. All drugs are listed by their generic names or most common proprietary (branded) name. Any drugs not found in this formulary listing or any formulary updates published by Express Scripts are considered non-formulary drugs and require prior authorization. All drugs are listed in each category in alphabetical order by generic or brand name. If the generic drug is FDA approved, it will appear italicized in the formulary listing. Covered brand drugs appear in CAPITALIZED font. Benefit Coverage and Limitations The Formulary applies only to outpatient drugs provided to members and does not apply to medications used in inpatient settings. If a member has any specific questions regarding their coverage, they should contact Wellfleet or Express Scripts at the phone numbers listed on their ID card. Excluded Agents Any drugs not listed in this print formulary are considered excluded from the drug benefit and are not covered. As new drugs become available, they will be considered for coverage under the Formulary. Non-Formulary and Step Therapy Exception Requests A member (or their appointed representative, prescribing physician, or authorized prescriber) may request a standard/non-urgent or expedited/urgent preservice/prior and current authorization for a drug that is subjected to utilization management tools such as step therapy. To initiate an exception request, contact 800-417-8164. Prior authorization guidelines will be made available to the member, member’s authorization representative, prescribing physician and other authorized prescriber upon request. PO Box 15369, Springfield, MA 01115 Copyright © 2019 Wellfleet Group, LLC. All rights reserved. www.wellfleetstudent.com i Table of Contents ANTI - INFECTIVES ........................................................................................................................................ 3 ANTINEOPLASTIC / IMMUNOSUPPRESSANT DRUGS ....................................................................... 22 AUTONOMIC / CNS DRUGS, NEUROLOGY / PSYCH ........................................................................... 36 CARDIOVASCULAR, HYPERTENSION / LIPIDS ................................................................................... 65 DERMATOLOGICALS/TOPICAL THERAPY .......................................................................................... 85 DIAGNOSTICS / MISCELLANEOUS AGENTS ...................................................................................... 102 EAR, NOSE / THROAT MEDICATIONS .................................................................................................. 113 ENDOCRINE/DIABETES ............................................................................................................................ 115 GASTROENTEROLOGY ............................................................................................................................ 151 IMMUNOLOGY, VACCINES / BIOTECHNOLOGY .............................................................................. 161 MUSCULOSKELETAL / RHEUMATOLOGY ......................................................................................... 170 OBSTETRICS / GYNECOLOGY ................................................................................................................ 173 OPHTHALMOLOGY ................................................................................................................................... 185 RESPIRATORY AND ALLERGY .............................................................................................................. 191 UROLOGICALS ............................................................................................................................................ 202 VITAMINS, HEMATINICS / ELECTROLYTES ..................................................................................... 204 Index ................................................................................................................................................................ 224 1 List of Abbreviations ACA: Affordable Care Act. OTC: Over the Counter. An OTC drug is a non-prescription drug. PA: Prior Authorization. The Plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval before you fill your prescriptions. If you don’t get approval, we may not cover the drug. QL: Quantity Limit. For certain drugs, the Plan limits the amount of the drug that we will cover. SP: Specialty ST: Step Therapy. In some cases, the Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. 2 Drug Name Drug Requirements Drug Name Drug Requirements Tier / Limits Tier / Limits ANTI - INFECTIVES fluconazole in nacl 1 PA (iso-osm) ANTIFUNGAL AGENTS intravenous ABELCET 2 piggyback 100 INTRAVENOUS mg/50 ml, 200 SUSPENSION 5 mg/100 ml, 400 MG/ML mg/200 ml AMBISOME 2 fluconazole oral 1 INTRAVENOUS suspension for SUSPENSION FOR reconstitution 10 RECONSTITUTIO mg/ml, 40 mg/ml N 50 MG fluconazole oral 1 AMPHOTERICIN B 2 tablet 100 mg, 200 (BULK) POWDER mg, 50 mg amphotericin b 1 fluconazole oral 1 QL injection recon soln tablet 150 mg 50 mg FLUCYTOSINE 2 caspofungin 1 (BULK) POWDER intravenous recon 100 % soln 50 mg, 70 mg flucytosine oral 1 clotrimazole mucous 1 capsule 250 mg, 500 membrane troche 10 mg mg griseofulvin 1 CRESEMBA 2 PA microsize oral INTRAVENOUS suspension 125 mg/5 RECON SOLN 372 ml MG griseofulvin 1 CRESEMBA ORAL 2 PA microsize oral tablet CAPSULE 186 MG 500 mg ERAXIS(WATER 2 griseofulvin 1 DILUENT) ultramicrosize oral INTRAVENOUS tablet 125 mg, 250 RECON SOLN 100 mg MG, 50 MG ITRACONAZOLE 2 FLUCONAZOLE 2 (BULK) POWDER (BULK) POWDER itraconazole oral 1 QL 100 % capsule 100 mg itraconazole oral 1 solution 10 mg/ml You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table. 3 Drug Name Drug Requirements Drug Name Drug Requirements Tier / Limits Tier / Limits KETOCONAZOLE 2 posaconazole oral 1 PA (BULK) POWDER tablet,delayed release (dr/ec) 100 ketoconazole oral 1 mg tablet 200 mg TERBINAFINE 2 micafungin 1 (BULK) POWDER intravenous recon 100 % soln 100 mg, 50 mg terbinafine hcl oral 1 MICONAZOLE 2 tablet 250 mg (BULK) POWDER VORICONAZOLE 2 MYCAMINE 2 (BULK) POWDER INTRAVENOUS 100 % RECON SOLN 100 MG, 50 MG voriconazole 1 PA intravenous recon NOXAFIL 2 PA soln 200 mg INTRAVENOUS SOLUTION 300 voriconazole oral 1 PA MG/16.7 ML suspension for reconstitution 200 NOXAFIL ORAL 2 PA mg/5 ml (40 mg/ml) SUSPENSION 200 MG/5 ML (40 voriconazole oral 1 PA MG/ML) tablet 200 mg, 50 mg NYSTATIN 2 ANTIVIRALS (BULK) POWDER abacavir oral 1 SP 1 BILLION UNIT, 1 solution 20 mg/ml MILLION UNIT, 10 BILLION UNIT, 15 abacavir oral tablet 1 SP BILLION UNIT, 300 mg 150 MILLION abacavir-lamivudine 1 SP UNIT, 2 BILLION oral tablet 600-300 UNIT, 5 BILLION mg UNIT, 50 MILLION UNIT, 500 abacavir- 1 SP MILLION UNIT lamivudine- zidovudine oral nystatin oral 1 tablet 300-150-300 suspension 100,000 mg unit/ml ACYCLOVIR 2 nystatin oral tablet 1 (BULK) POWDER 500,000 unit 100 % acyclovir oral 1 capsule 200 mg You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table. 4 Drug Name Drug Requirements Drug Name Drug Requirements Tier / Limits Tier / Limits acyclovir oral 1 cidofovir 1 suspension 200 mg/5 intravenous solution ml 75 mg/ml acyclovir oral tablet 1 CIMDUO ORAL 2 SP 400 mg, 800 mg TABLET 300-300 MG acyclovir sodium 1 intravenous recon CRIXIVAN ORAL 2 SP soln 1,000 mg, 500 CAPSULE 200 MG mg DESCOVY ORAL 2 SP acyclovir sodium 1 TABLET 200-25 intravenous solution MG 50 mg/ml didanosine oral 1 SP adefovir oral tablet 1 capsule,delayed 10 mg release(dr/ec) 250 mg, 400 mg AMANTADINE 2 HCL (BULK) DOVATO ORAL 2 SP POWDER TABLET 50-300 MG amantadine hcl oral 1 capsule 100 mg EDURANT ORAL 2 SP TABLET 25 MG amantadine hcl oral 1 solution 50 mg/5 ml efavirenz oral 1 SP capsule 200 mg, 50 amantadine hcl oral 1 mg tablet 100 mg efavirenz oral tablet 1 SP APTIVUS (WITH 2 SP 600 mg VITAMIN E) ORAL SOLUTION 100 efavirenz- 1 SP MG/ML emtricitabin-tenofov oral tablet 600-200- APTIVUS ORAL 2 SP 300 mg CAPSULE 250 MG efavirenz-lamivu- 1 SP atazanavir oral 1 SP tenofov disop oral capsule 150 mg, 200 tablet 400-300-300 mg, 300 mg mg, 600-300-300 mg BARACLUDE 2 emtricitabine oral 1 SP ORAL SOLUTION capsule 200 mg 0.05 MG/ML emtricitabine- 1 SP; ACA BIKTARVY ORAL 2 SP tenofovir (tdf) oral TABLET 50-200-25 tablet 200-300 mg MG You can find information on what the symbols and abbreviations on this table mean by going to the beginning of this table. 5 Drug Name Drug Requirements Drug Name Drug Requirements Tier / Limits Tier / Limits EMTRIVA ORAL 2 SP INTELENCE ORAL 2 SP SOLUTION 10 TABLET 100 MG, MG/ML 200 MG, 25 MG entecavir oral tablet 1 INVIRASE ORAL 2 SP 0.5 mg, 1 mg TABLET 500 MG EPCLUSA ORAL 2 PA; SP; QL ISENTRESS HD 2 SP TABLET 200-50 ORAL TABLET MG, 400-100 MG 600 MG EPIVIR HBV 2 ISENTRESS ORAL 2 SP ORAL SOLUTION POWDER IN 25 MG/5 ML (5 PACKET 100 MG MG/ML) ISENTRESS ORAL 2 SP famciclovir oral 1 QL TABLET 400 MG tablet 125 mg, 250 ISENTRESS ORAL 2 SP mg, 500 mg TABLET,CHEWAB fosamprenavir oral 1 SP LE
Recommended publications
  • Current Status of Local Penile Therapy

    Current Status of Local Penile Therapy

    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
  • Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits

    Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits

    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS ORIGINAL ARTICLE Volume 00, Number 0, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/jop.2013.0075 Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits Ama´lia Turner Giannico,1 Leandro Lima,1 Heloisa Helena Abil Russ,2 and Fabiano Montiani-Ferreira1 Abstract Purpose: Prostaglandin analogues (PGA) are ocular hypotensive agents used for the treatment of glaucoma. Hypertrichosis of the eyelashes has been reported in humans as a side effect. Eyelash growth was investigated with clinical trials in people using bimatoprost. Scattered reports of eyelash growth during the treatment of glaucoma with other PGA are also found in the literature. We investigated the effect of 4 different topical PGA on eyelash length. Methods: Forty New Zealand white rabbits were divided into 4 groups and received daily topical application of bimatoprost, tafluprost, travoprost, and latanoprost in the left eye for 4 weeks. The right eye received no treatment. Eyelash length was measured in both eyes before and after treatment using a stainless steel digital caliper. Results: Bimatoprost and tafluprost groups had significant increases in eyelash length. We did not observe significant eyelash growth in rabbits receiving travoprost and latanoprost after 1 month of treatment. Conclusions: Today, only bimatoprost is approved for growing eyelashes, and our research shows that ta- fluprost could be further explored by the cosmetic and pharmaceutical industry. Additional research using travoprost and latanoprost as agents for eyelash growth should be performed in the future using prolonged treatment periods to determinate whether or not these PGA induce eyelash growth, and investigate other possible side effects.
  • Totalcare Medicaid 2017 Q2 GB

    Totalcare Medicaid 2017 Q2 GB

    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
  • New Directions for Erectile Dysfunction Therapies

    New Directions for Erectile Dysfunction Therapies

    International Journal of Impotence Research (2002) 14, Suppl 1, S82–S92 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir New directions for erectile dysfunction therapies K-E Andersson1* and P Hedlund1 1Department of Clinical Pharmacology, Lund University Hospital, S-22185, Lund, Sweden Research in the field of erectile function and dysfunction has continued to expand rapidly. Based on the information available, some directions for future erectile dysfunction therapies can be identified. The first direction is improvement of current therapeutic principles. A second generation of orally active phosphodiesterase (PDE) inhibitors is being introduced, and further developments within this field can be expected. The recent introduction of apomorphine has opened the way for new dopamine receptor agonists. The second direction is combinations of existing therapeutic principles. Combinations of apomorphine and sildenafil and apomorphine and a1-adrenoceptor (AR) antagonists, for example, seem attractive and may have a therapeutic potential in patients not responding satisfactorily to single-drug treatment. Nitrosylated a1-AR antagonists, combining nitric oxide donation and a1-ora2-AR antagonism, are currently being evaluated. The third direction is new targets within the central nervous system. Melanocortin receptor agonists have shown promise not only in animal models, but also in preliminary studies in humans. Other possible targets, such as growth hormone-releasing peptide receptors, are being explored. The fourth direction is new peripheral targets. Rho-kinase antagonism and non-nitric oxide-mediated stimulation of soluble guanylyl cyclase have been suggested as possible new principles for drug development. The fourth direction is gene therapy. Progress has been made in intracavernosal somatic gene therapy and will probably continue.
  • Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice

    Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice

    Effect of Bimatoprost on Intraocular Pressure in Prostaglandin FP Receptor Knockout Mice Jonathan G. Crowston,1 James D. Lindsey,1 Christy A. Morris,1 Larry Wheeler,2 Felipe A. Medeiros,1 and Robert N. Weinreb1 PURPOSE. To determine the effect of bimatoprost on intraocular ing are not known, it has been suggested that bimatoprost pressure in the prostaglandin FP receptor knockout mouse. fundamentally differs from latanoprost, by lowering IOP ETHODS ␮ ␮ through mechanisms that are independent of FP receptor sig- M . The IOP response to a single 1.2- g(4 L) dose of 5 bimatoprost was measured in the treated and untreated fellow naling. However, there is considerable controversy regarding eyes of homozygote (FPϩ/ϩ, n ϭ 9) and heterozygote (FPϮ, n the role of FP receptor signaling, because bimatoprost has ϭ been shown to bind and activate the FP receptor in cultured 10) FP-knockout mice, as well as in wild-type C57BL/6 mice 6 (FPϩ/ϩ, n ϭ 20). Serial IOP measurements were also per- human trabecular meshwork and human ciliary muscle cells. Measurement of aqueous humor dynamics in the mouse eye formed after topical bimatoprost in a separate generation of 7 homozygous FP-knockout mice and wild-type littermate con- has been detailed recently. The FP knockout mouse, gener- trol animals (n ϭ 4 per group). Aqueous humor protein ated by homologous translocation with a target vector that ␤ concentrations were measured to establish the state of the replaces the second exon of the FP gene with the -galactosi- blood–aqueous barrier. Tissue, aqueous humor and vitreous dase and neomycin-resistance gene, was produced to demon- strate the critical role of the interaction of PGF2␣ with FP concentrations of bimatoprost, latanoprost, and their C-1 free 8 acids were determined by liquid chromatography and tandem receptors in the initiation of parturition in pregnant mice.
  • Pharmacology of Ophthalmic Agents

    Pharmacology of Ophthalmic Agents

    Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S.
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
  • New Zealand Data Sheet 1. Product Name 2. Qualitative

    New Zealand Data Sheet 1. Product Name 2. Qualitative

    NEW ZEALAND DATA SHEET BIMATOPROST MULTICHEM 1. PRODUCT NAME Bimatoprost multichem 0.3 mg/mL eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL contains 0.3 mg bimatoprost. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Bimatoprost multichem eye drops are a clear, isotonic, colourless, sterile ophthalmic solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Bimatoprost multichem is indicated as monotherapy for the reduction of elevated intraocular pressure (IOP) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents. 4.2 Dose and method of administration Monotherapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. Adjunctive therapy The recommended dose is one drop of Bimatoprost multichem in the affected eye(s) once daily, administered in the evening. More frequent administration has not been shown to provide increased efficacy. If more than one topical ophthalmic medication is to be used, the other medication should not be used within 5 minutes of using Bimatoprost multichem eye drops. In order to minimise systemic absorption of Bimatoprost multichem eye drops, patients should be instructed to apply pressure to the tear duct immediately following administration of the drug. Paediatric use Safety and effectiveness in patients below 18 years of age has not been established. Use in elderly No dosage adjustment in elderly patients is necessary. 4.3 Contraindications Bimatoprost multichem eye drops are contraindicated in patients with hypersensitivity to bimatoprost or to any component of the medication.
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub

    US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g.
  • Treatment of Eyebrow Hypotrichosis Using Bimatoprost: a Randomized, Double-Blind, Vehicle-Controlled Pilot Study

    Treatment of Eyebrow Hypotrichosis Using Bimatoprost: a Randomized, Double-Blind, Vehicle-Controlled Pilot Study

    ORIGINAL ARTICLE Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study † KENNETH R. BEER, MD,* HILLARY JULIUS, PA,* MONICA DUNN, RN,* AND FRED WILSON,MS BACKGROUND The Food and Drug Administration has approved bimatoprost ophthalmic solution (0.03%) for the treatment of eyelash hypotrichosis. Previous reports of its efficacy in eyebrow hypotrichosis are anecdotal. OBJECTIVE To assess the efficacy and safety of bimatoprost 0.03% ophthalmic solution applied to the eyebrows in a randomized, double-blind, vehicle-controlled study. METHODS Subjects (n = 20) with mild to moderate eyebrow hypotrichosis enrolled in the study. One group (Bim) applied bimatoprost to each eyebrow daily for 9 months, and another applied vehicle nightly to each eyebrow for 5 months. Subjects in the latter group were re-randomized to apply bimatoprost (Veh-Bim Group) or vehicle (Veh Group) daily to each eyebrow for 4 months. The primary end point was investigator-assessed eyebrow appearance; secondary end points were subject-reported outcomes. RESULTS Investigator assessments showed significant improvements from baseline to 6 (p = .002) and 7 (p = .005) months for the eyebrows treated with bimatoprost. p-Values for the Veh-Bim and Veh groups were not significant at any time point. End-of-study subject satisfaction with eyebrow fullness or thickness and darkness or color was greater in the Bim group than in the Veh group. Adverse effects were not observed. CONCLUSION Bimatoprost 0.03% ophthalmic solution applied daily for 9 months improves the appearance of eyebrows noticeably more than vehicle, without side effects. This study was funded with a research grant by Allergan, Inc.
  • API Manufacturing

    API Manufacturing

    API Manufacturing The Importance of Process Understanding When it comes to process understanding and commercial manufacturing, no other manufacturer can match Cayman’s knowledge of prostaglandin chemistry. We are the industry leaders in prostaglandin synthesis with over 30 years of experience. Our expert chemists use this knowledge daily to synthesize commercially available eicosanoids as active pharmaceutical ingredients (APIs). Our talented team of scientists in Ann Arbor, Michigan, USA and Neratovice, Czech Republic has filed numerous patents for the complex synthesis and commercial manufacture of over seven APIs with additional compounds currently under development. OPH Cayman’s Center of Excellence in Ann Arbor focuses primarily on the synthesis, scale-up, and registration of new API manufacturing processes. Once registration batches have been completed, the GMP portion of the process and all supporting documentation are transferred to our commercial manufacturing Center of Excellence in Neratovice. The facility at Cayman Pharma has over 30 years of commercial prostaglandin and eicosanoid registration and manufacturing experience, is ISO certified, and has an excellent track record with customers and regulatory authorities VA S worldwide, including being US FDA and EMA compliant. Commercial API production We currently manufacture the following APIs according to the latest ICH and CGMP requirements for commercial distribution. Contact our sales department for more information about pricing and availability. VET · CGMP Bimatoprost · CGMP Latanoprost · CGMP Tafluprost · CGMP Travoprost · CGMP Epoprostenol (sodium salt) CS · CGMP (+)-Cloprostenol (sodium salt) · CGMP (±)-Cloprostenol (sodium salt) Development API production · Alfaprostol · Latanoprostene Bunod · Treprostinil (sodium salt) Cayman Pharma s.r.o. Phone: (+420) 315 664 381 [email protected] 2019 CAYMAN PHARMA S.R.O.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.